 countries in the global south, then it's a non-starter. Those countries just aren't going to be able to afford it. Gilead has said it's going to work to make the prevention tool affordable, but they haven't yet set a price. And they've also said that they're going to work with generic manufacturers so that they can produce a version of it that will be more affordable as well. But really, that's years in the future before we're going to see generic versions of linacapavir. And how big a deal would you say this is in terms of, I don't know, the history of the HIV epidemic?